At least one 12-lead ECG or other single- or multiple-lead ECG device (e.g. Holter monitor-ing or ECG-providing wearables) documented episode during 6 months prior to inclusion
\* Paroxysmal AF in this trial is defined as at least 2 episodes, either self-terminating or cardioverted within 7 days, during 6 months prior to in-clusion
\*\*Persistent AF in this study is defined as the following:
Duration of an AF episode \>7 days and \< 6 months
Total documented AF history \< 5 years
You may not be if
Atrial flutter as the primary arrhythmia. (Patients with previous or isolated episodes of atrial flutter may be included, provided that AF is the dominant arrhythmia and the primary target of clinical management)
Implanted electronic device (pacemaker/ICD/ICM)
Type 1 diabetes or Type 2 diabetes on insulin treatment
Severe heart failure (LVEF \<40%)
Inability to sign informed consent
Severe kidney disease (eGFR\<30)
History of catheter ablation for AF
Scheduled to receive catheter ablation for AF during the study period (next 1 year)
Incretin-based therapy (GLP-1 receptor agonists or DPP-IV inhibitors) within 30 days prior to randomization (visit 1)
Scheduled for bariatric surgery during the study period
Hypertrophic cardiomyopathy, ARVC/D, non-compaction or amyloidosis
Chronic or previous acute pancreatitis
Current participation in any other clinical intervention trial that may result in changes to med-ical management during the study period
Women of childbearing potential who are not on an acceptable form of contraception
Pregnant or breastfeeding women
Personal or family history of medullary thyroid carcinoma (MTC)
History of MEN2 (Multiple Endocrine Neoplasia type 2)
Clareo Health | Danish Trial of Weight Loss to Reduce Atrial Fibrillation Progression
